Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 16;51(1):108.
doi: 10.1007/s11033-023-09135-4.

"Combination treatments of imatinib with astaxanthin and crocin efficiently ameliorate antioxidant status, inflammation and cell death progression in imatinib-resistant chronic myeloid leukemia cells"

Amin Golestani  1 , Atefeh Rahimi  1 , Mahsa Najafzadeh  1 , Mahtab Sayadi  2 , Seyed Mehdi Sajjadi  3
Affiliations

"Combination treatments of imatinib with astaxanthin and crocin efficiently ameliorate antioxidant status, inflammation and cell death progression in imatinib-resistant chronic myeloid leukemia cells"

Amin Golestani et al. Mol Biol Rep. .

Abstract

Background: Imatinib resistance remains a major obstacle in the treatment of chronic myelogenous leukemia (CML). Crocin (CRC) and astaxanthin (ATX) are phytochemicals with anti-cancer properties.

Aims: This study aimed to explore the effects of combination treatment of Imatinib with CRC and ATX on Imatinib-resistant K562 (IR-K562) cells.

Methods and results: After the establishment of IR-K562 cells, growth inhibitory activity was determined by the MTT assay. To test the regeneration potential, a colony formation assay was performed. Cell cycle analyses were examined by flow cytometry. Cell injury was evaluated by lactate dehydrogenase (LDH) leakage. Real-time PCR was applied to assess the expression of IL6, TNF-α, STAT3, BAD, CASP3, TP53, and Bcl-2 genes. Caspase-3 activity was determined by a colorimetric assay. Antioxidant activity was measured using a diphenylpicrylhydrazyl (DPPH) assay. After 48 h of treatment, ATX (IC50 = 30µM) and CRC (IC50 = 190µM) significantly inhibited cell proliferation and colony formation ability, induced G1 cell cycle arrest and cell injury, upregulated the expression of apoptosis-associated genes, and downregulated the expression of anti-apoptotic and inflammatory genes. The combination of IM with ATX and/or CRC synergistically reduced cell viability (combination index [CI] < 1).

Conclusion: Our data suggest that IM shows better therapeutic efficacy at lower doses when combined with ATX and/or CRC.

Keywords: Astaxanthin; Chronic myeloid leukemia; Crocin; Drug resistance; Imatinib; K562 cells.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Soverini S, De Benedittis C, Mancini M, Martinelli G (2016) Best practices in chronic Myeloid Leukemia monitoring and management. Oncologist 21:626–633 - DOI - PubMed - PMC
    1. Cai H, Li L, Jiang J, Zhao C, Yang C (2019) Costunolide enhances sensitivity of K562/ADR chronic Myeloid Leukemia cells to doxorubicin through PI3K/Akt pathway. Phytother Res 33:1683–1688. https://doi.org/10.1002/ptr.6355 - DOI - PubMed
    1. Zhao M, Yang C, Chai S, Yuan Y, Zhang J, Cao P, Wang Y, Xiao X, Wu K, Yan H, Liu J, Sun S (2021) Curcumol and FTY720 synergistically induce apoptosis and differentiation in chronic myelomonocytic Leukemia via multiple signaling pathways. Phytother Res 35:2157–2170. https://doi.org/10.1002/ptr.6968 - DOI - PubMed
    1. Kang Y, Hodges A, Ong E, Roberts W, Piermarocchi C, Paternostro G (2014) Identification of drug combinations containing imatinib for treatment of BCR-ABL + leukemias. PLoS ONE 9:e102221 - DOI - PubMed - PMC
    1. Jabbour EJ, Hughes TP, Cortés JE, Kantarjian HM, Hochhaus A (2014) Potential mechanisms of Disease progression and management of advanced-phase chronic Myeloid Leukemia. Leuk Lymphoma 55:1451–1462 - DOI - PubMed

LinkOut - more resources